Voruciclib dosing regimens and methods of treatment including the same
AssigneeMEI Pharma, Inc.
InventorsDaniel GOLD, Alan F. PARR
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a formulation comprising voruciclib malonate. The present disclosure further provides a method of treating a blood cancer using the formulation and an optional BCL-2 inhibitor, administered on various dosage regimens.
Claims52
A formulation comprising between about 15% to about 35% w/w voruciclib malonate and one or more pharmaceutically acceptable excipients.
A method of treating a disease or disorder in a subject, the method comprising administering to the subject a therapeutically effective of a formulation comprising between about 15% to 35% w/w voruciclib malonate, about 5% to 37% w/w microcrystalline cellulose, about 1% to about 48% w/w lactose monohydrate, about 20% to about 70% w/w dibasic calcium phosphate dihydrate, about 0.1% to about 15% w/w sodium bicarbonate, about 1% to about 20% w/w sodium starch glycolate, and about 0.01% to about 10% w/w magnesium stearate.
Dependencies are inferred from the claim text.